The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance provisions of the Competition Act (the Act), relating to ustekinumab (Janssen’s ...
As the company with the largest generic drug portfolio in Canada ¹, the JAMP Pharma Group is proud to offer a cost-effective therapeutic option for patients suffering from rare and severe lung ...
The MarketWatch News Department was not involved in the creation of this content. A new generic option of Enzalutamide, an oncology medication used for the treatment of certain stages of prostate ...
JAMP filed an application with the Competition Tribunal on July 26, 2024, seeking leave to bring an abuse of dominance case against Janssen relating to ustekinumab (Janssen’s STELARA). JAMP proposes ...
Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market High-concentration ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Both the ...
PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ...
A new generic option of Enzalutamide, an oncology medication used for the treatment of certain stages of prostate cancer 2. It is an orally administered antiandrogen. JAMP Pharma Group is launching Pr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results